Minireview: Epigenetic changes in ovarian cancer

Curt Balch, Fang Fang, Daniela E. Matei, Tim H M Huang, Kenneth P. Nephew

Research output: Contribution to journalShort survey

106 Citations (Scopus)

Abstract

Epigenetic aberrations, including DNA methylation, histone modifications, and micro-RNA dysregulation, are now well established in the development and progression of ovarian cancer, and their gradual accumulation is associated with advancing disease stage and grade. Epigenetic aberrations are relatively stable, associated with distinct disease subtypes, and present in circulating serum, representing promising diagnostic, prognostic, and pharmacodynamic biomarkers. In contrast to DNA mutations and deletions, aberrant gene-repressive epigenetic modifications are potentially reversible by epigenetic therapies, including inhibitors of DNA methylation or histone-modifying enzymes. Although epigenetic monotherapies have not shown activity against solid tumors, including ovarian cancer, preclinical studies suggest they will be effective when used in combination with one another or with conventional chemotherapeutics, and combinatorial epigenetic therapy regiments are being examined in cancer clinical trials. A greater understanding of the role of epigenetics in ovarian neoplasia will provide for improved interventions against this devastating malignancy.

Original languageEnglish (US)
Pages (from-to)4003-4011
Number of pages9
JournalEndocrinology
Volume150
Issue number9
DOIs
StatePublished - Sep 1 2009

Fingerprint

Epigenomics
Ovarian Neoplasms
DNA Methylation
Neoplasms
Histone Code
Sequence Deletion
Gene Deletion
MicroRNAs
Histones
Biomarkers
Clinical Trials
DNA
Enzymes
Therapeutics
Serum

ASJC Scopus subject areas

  • Endocrinology

Cite this

Balch, C., Fang, F., Matei, D. E., Huang, T. H. M., & Nephew, K. P. (2009). Minireview: Epigenetic changes in ovarian cancer. Endocrinology, 150(9), 4003-4011. https://doi.org/10.1210/en.2009-0404
Balch, Curt ; Fang, Fang ; Matei, Daniela E. ; Huang, Tim H M ; Nephew, Kenneth P. / Minireview : Epigenetic changes in ovarian cancer. In: Endocrinology. 2009 ; Vol. 150, No. 9. pp. 4003-4011.
@article{600c10fe81444352b04c4958dcdc2fed,
title = "Minireview: Epigenetic changes in ovarian cancer",
abstract = "Epigenetic aberrations, including DNA methylation, histone modifications, and micro-RNA dysregulation, are now well established in the development and progression of ovarian cancer, and their gradual accumulation is associated with advancing disease stage and grade. Epigenetic aberrations are relatively stable, associated with distinct disease subtypes, and present in circulating serum, representing promising diagnostic, prognostic, and pharmacodynamic biomarkers. In contrast to DNA mutations and deletions, aberrant gene-repressive epigenetic modifications are potentially reversible by epigenetic therapies, including inhibitors of DNA methylation or histone-modifying enzymes. Although epigenetic monotherapies have not shown activity against solid tumors, including ovarian cancer, preclinical studies suggest they will be effective when used in combination with one another or with conventional chemotherapeutics, and combinatorial epigenetic therapy regiments are being examined in cancer clinical trials. A greater understanding of the role of epigenetics in ovarian neoplasia will provide for improved interventions against this devastating malignancy.",
author = "Curt Balch and Fang Fang and Matei, {Daniela E.} and Huang, {Tim H M} and Nephew, {Kenneth P.}",
year = "2009",
month = "9",
day = "1",
doi = "10.1210/en.2009-0404",
language = "English (US)",
volume = "150",
pages = "4003--4011",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "9",

}

Balch, C, Fang, F, Matei, DE, Huang, THM & Nephew, KP 2009, 'Minireview: Epigenetic changes in ovarian cancer', Endocrinology, vol. 150, no. 9, pp. 4003-4011. https://doi.org/10.1210/en.2009-0404

Minireview : Epigenetic changes in ovarian cancer. / Balch, Curt; Fang, Fang; Matei, Daniela E.; Huang, Tim H M; Nephew, Kenneth P.

In: Endocrinology, Vol. 150, No. 9, 01.09.2009, p. 4003-4011.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - Minireview

T2 - Epigenetic changes in ovarian cancer

AU - Balch, Curt

AU - Fang, Fang

AU - Matei, Daniela E.

AU - Huang, Tim H M

AU - Nephew, Kenneth P.

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Epigenetic aberrations, including DNA methylation, histone modifications, and micro-RNA dysregulation, are now well established in the development and progression of ovarian cancer, and their gradual accumulation is associated with advancing disease stage and grade. Epigenetic aberrations are relatively stable, associated with distinct disease subtypes, and present in circulating serum, representing promising diagnostic, prognostic, and pharmacodynamic biomarkers. In contrast to DNA mutations and deletions, aberrant gene-repressive epigenetic modifications are potentially reversible by epigenetic therapies, including inhibitors of DNA methylation or histone-modifying enzymes. Although epigenetic monotherapies have not shown activity against solid tumors, including ovarian cancer, preclinical studies suggest they will be effective when used in combination with one another or with conventional chemotherapeutics, and combinatorial epigenetic therapy regiments are being examined in cancer clinical trials. A greater understanding of the role of epigenetics in ovarian neoplasia will provide for improved interventions against this devastating malignancy.

AB - Epigenetic aberrations, including DNA methylation, histone modifications, and micro-RNA dysregulation, are now well established in the development and progression of ovarian cancer, and their gradual accumulation is associated with advancing disease stage and grade. Epigenetic aberrations are relatively stable, associated with distinct disease subtypes, and present in circulating serum, representing promising diagnostic, prognostic, and pharmacodynamic biomarkers. In contrast to DNA mutations and deletions, aberrant gene-repressive epigenetic modifications are potentially reversible by epigenetic therapies, including inhibitors of DNA methylation or histone-modifying enzymes. Although epigenetic monotherapies have not shown activity against solid tumors, including ovarian cancer, preclinical studies suggest they will be effective when used in combination with one another or with conventional chemotherapeutics, and combinatorial epigenetic therapy regiments are being examined in cancer clinical trials. A greater understanding of the role of epigenetics in ovarian neoplasia will provide for improved interventions against this devastating malignancy.

UR - http://www.scopus.com/inward/record.url?scp=69249145317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249145317&partnerID=8YFLogxK

U2 - 10.1210/en.2009-0404

DO - 10.1210/en.2009-0404

M3 - Short survey

C2 - 19574400

AN - SCOPUS:69249145317

VL - 150

SP - 4003

EP - 4011

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 9

ER -

Balch C, Fang F, Matei DE, Huang THM, Nephew KP. Minireview: Epigenetic changes in ovarian cancer. Endocrinology. 2009 Sep 1;150(9):4003-4011. https://doi.org/10.1210/en.2009-0404